Anika Therapeutics ANIK Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$5.06M-3.8% | $0+100% | -$2.33M+92.2% | -$3.97M-4,411% | -$4.87M-8.0% | ||
| $1.41M+1.7% | $1.32M-15.5% | $1.39M-25.2% | $1.28M-26.0% | $1.38M-20.2% | ||
| $6.64M+132% | $2.46M+9.0% | $2.22M-34.7% | $2.55M-34.5% | $2.86M-20.3% | ||
| $108K+500% | -$25K-111% | $3K— | -$3K-118% | $18K-90.7% | ||
| $52K-82.7% | —— | $451K+565% | $205K— | $300K— | ||
| $2.18M+172% | —— | -$1.29M+72.9% | —— | -$3.03M+16.3% | ||
| $5.41M+1,134% | —— | —— | -$1.73M-137% | -$523K-113% | ||
| $745K+1,485% | $877K+825% | $231K+108% | -$1.11M-852% | $47K-88.3% | ||
| -$1.34M+56.6% | —— | —— | -$2.16M-18.6% | -$3.09M+0.7% | ||
| $1.73M+751% | -$1.31M-2,328% | -$219K— | -$1M+21.5% | $203K-63.0% | ||
| $1.19M+9,254% | —— | -$21K-102% | -$435K+42.8% | -$13K-114% | ||
| $464K-19.6% | $499K-15.3% | $495K-15.5% | $490K+19.5% | $577K+2.1% | ||
| -$4.85M-3,628% | $4.64M+193% | $6.87M+37.0% | -$189K+82.3% | -$130K-3.2% | ||
| $1.43M-49.3% | $648K-50.4% | $1.89M+55.2% | $1.47M-56.9% | $2.82M+56.2% | ||
| $0-100% | —— | —— | —— | $4.5M— | ||
| -$1.24M-174% | —— | -$1.73M+4.6% | —— | $1.67M+192% | ||
| $8.69M+119% | $5.51M-1.1% | —— | —— | $3.97M— | ||
| $1.66M+13.0% | $4K-94.7% | $13K-40.9% | $82K-60.0% | $1.47M-36.1% | ||
| -$10.35M-90.3% | -$5.28M+1.4% | -$13K+99.7% | $0+100% | -$5.44M-139% | ||
| -$29K-127% | —— | —— | $345K+254% | $108K+448% | ||
| -$16.46M-335% | —— | $4.82M+1,162% | -$204K+96.5% | -$3.79M+10.6% | ||
| —— | $269K-73.1% | $269K-73.1% | $269K-73.1% | $269K-73.1% | ||
| $52K-82.7% | —— | $451K+565% | $205K— | $300K— | ||
| $1.73M+751% | -$1.31M-2,328% | -$219K— | -$1M+21.5% | $203K-63.0% | ||
| $1.03M+24.0% | $852K-95.4% | $1.13M-95.2% | $3.01M+346% | $832K-59.7% | ||
| $464K-19.6% | $499K-15.3% | $495K-15.5% | $490K+19.5% | $577K+2.1% | ||
| $192K— | $846K— | $155K— | $328K— | $0— | ||
| $0-100% | —— | —— | —— | $4.5M— | ||
| $0-100% | $0-100% | $12K-96.3% | $136K-58.5% | $209K-36.5% | ||
| $55K-89.0% | $630K+20.9% | —— | $318K— | $502K-19.3% | ||
| -$29K-127% | —— | —— | $345K+254% | $108K+448% | ||
| -$468K+17.8% | -$471K+18.4% | -$480K+15.3% | -$476K-21.4% | -$569K-4.2% | ||
| $179K-20.1% | $472K— | $79K— | $121K— | $224K— | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| -$24K+93.1% | $56K-65.4% | $76K-91.7% | $479K+4,690% | -$346K-472% | ||
| —— | $269K-73.1% | $269K-73.1% | $269K-73.1% | $269K-73.1% | ||
| -$6.28M-112% | $3.99M— | $4.98M— | -$1.66M+63.0% | -$2.95M-52.7% | ||
| -$6.28M-112% | $3.99M— | $4.98M— | -$1.66M+63.0% | -$2.95M-52.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Anika Therapeutics generate?
- Anika Therapeutics (ANIK) generated $6.5M in operating cash flow over the trailing twelve months.
- What is Anika Therapeutics's free cash flow?
- After $5.4M of capital expenditures, Anika Therapeutics's free cash flow was $1.0M over the trailing twelve months, up 105.4% year over year.
- Where does Anika Therapeutics's cash flow data come from?
- Every line is extracted from Anika Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
